The decision comes as the company reported a net loss of $223.6 million and an operating margin of a negative 4.3% last year.

The pharmaceutical giant sued Strive and several other compounders for distributing products containing tirzepatide, the primary ingredient in Lilly's GLP-1 weight-loss and diabetes medications.

The plans average 120 catastrophic diagnoses per year per 100,000 enrollees, a care manager reports.

While “many technology vendors are working to build AI agents,” numerous solutions are actually rebrands of existing products meant to capture buyers’ attention, says Eser Rizaoglu, senior director analyst in Gartner’s HR Practice.